Document Detail


Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients.
MedLine Citation:
PMID:  8605789     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To assess the efficacy, usefulness, safety, and dosages of flumazenil required when flumazenil is used in the diagnosis of benzodiazepine-induced coma (vs. other drug-induced coma), and to reverse or prevent the recurrence of unconsciousness. DESIGN: A two-phase study: a controlled, randomized, double-blind study followed by a prospective, open study. SETTING: An 800-bed, teaching, university-affiliated hospital. PATIENTS: Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist. The first 31 patients were studied in a double-blind fashion, while the rest of the patients were given flumazenil according to an open protocol. INTERVENTIONS; All patients received supplemental oxygen; endotracheal intubation was performed, and synchronized intermittent mandatory ventilation was initiated whenever it was deemed necessary. A peripheral intravenous cannula was inserted, as were indwelling arterial and urinary bladder catheters. Blood pressure, electrocardiogram, respiratory rate, end-tidal CO2, and core temperature were continuously monitored. The first 31 double-blind patients received either intravenous flumazenil (to a maximum of 1 mg) or saline, while the rest of the patients were given flumazenil until either regaining consciousness or a maximum of 2.5 mg was injected. Patients remaining unconscious among double-blind patients or those patients relapsing into coma after the first dose were later treated in the open phase of the study. Treatment continued by boluses or infusion as long as efficacious. MEASUREMENTS AND MAIN RESULTS: Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations. Twenty-five percent of the patients did not regain consciousness. These patients had very high serum concentrations of nonbenzodiazepine drugs. Sixty percent of the responders who had primarily ingested benzodiazepines remained awake for 72 +/- 37 mins after flumazenil administration; 40% relapsed into coma after 18 +/- 7 mins and various central nervous system depressant drugs were detected in their blood in addition to benzodiazepines. Seventy-one percent of the patients had ingested tricyclic antidepressants. Seventy-eight percent of the responders were continually and efficaciously treated for < or = 8 days. Fourteen (25%) of the intubated patients were extubated safely while 12 patients, who had shown increased respiratory insufficiency, resumed satisfactory respiration after flumazenil injection. Five cases of transient increase in blood pressure and heart rate were encountered. There were 27 mildly unpleasant "waking" episodes, such as anxiety, restlessness, and aggression, but no patient had benzodiazepine withdrawal signs, convulsions, or dysrhythmia, most noticeably absent in tricyclic antidepressant-intoxicated patients. CONCLUSIONS: Flumazenil is a valid diagnostic tool for distinguishing pure benzodiazepine from mixed-drug intoxication or nondrug-induced coma. Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma. Respiratory insufficiency is reversed after its administration. Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants.
Authors:
A Weinbroum; V Rudick; P Sorkine; Y Nevo; P Halpern; E Geller; D Niv
Related Documents :
17646499 - Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea d...
17473639 - Lung function in congenital kyphosis and kyphoscoliosis.
11056729 - Effects on respiratory function of the head-down position and the complete covering of ...
2246169 - Physiology of aging related to outcome in the adult respiratory distress syndrome.
2791679 - Neural respiratory drive and neuromuscular coupling during co2 rebreathing in patients ...
22622349 - Increased rectal microbial richness is associated with the presence of colorectal adeno...
19930839 - Impact of obstructive sleep apnoea on clinical characteristics and outcomes in patients...
16938379 - Lymphocytes from patients with early stage of b-cell chronic lymphocytic leukaemia and ...
17627709 - Ageing in marfan syndrome.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Critical care medicine     Volume:  24     ISSN:  0090-3493     ISO Abbreviation:  Crit. Care Med.     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-05-22     Completed Date:  1996-05-22     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0355501     Medline TA:  Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  199-206     Citation Subset:  AIM; IM    
Affiliation:
Department of Anesthesiology and Critical Care Medicine, Tel-Aviv-Elias Sourasky Medical Center, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antidepressive Agents, Tricyclic / poisoning
Antidotes / diagnostic use*,  therapeutic use*
Barbiturates / poisoning
Benzodiazepines / blood,  poisoning
Coma / blood,  chemically induced*,  drug therapy*
Diagnosis, Differential
Double-Blind Method
Female
Flumazenil / diagnostic use*,  therapeutic use*
Humans
Male
Middle Aged
Prospective Studies
Recurrence
Reproducibility of Results
Chemical
Reg. No./Substance:
0/Antidepressive Agents, Tricyclic; 0/Antidotes; 0/Barbiturates; 12794-10-4/Benzodiazepines; 78755-81-4/Flumazenil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute renal failure in intensive care units--causes, outcome, and prognostic factors of hospital mor...
Next Document:  Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with s...